Hyperlipen (Ciprofibrate)

Ciprofibrate activates the nuclear receptor PPARα, which increases the expression of enzymes involved in fatty‑acid oxidation. This accelerates the breakdown of triglyceride‑rich lipoproteins and reduces hepatic production of VLDL, resulting in lower plasma triglyceride concentrations.

The specific dose of Hyperlipen is determined by the prescribing clinician based on the patient’s lipid profile, renal and hepatic function, and other individual factors. Dosage adjustments should follow the prescriber’s instructions and local prescribing guidelines.

Safety of ciprofibrate in pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Hyperlipen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Compared with statins, ciprofibrate primarily reduces triglycerides and modestly raises HDL‑cholesterol, whereas statins mainly lower LDL‑cholesterol. Fibrates like Hyperlipen are often chosen when triglyceride reduction is the primary therapeutic goal or when statin therapy alone is insufficient.

Hyperlipen should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Hyperlipen is taken orally, usually with a meal to improve absorption and reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not crushed or chewed, unless otherwise directed by a healthcare provider.

The most serious adverse events include myopathy or rhabdomyolysis, especially when combined with statins, significant liver enzyme elevations indicating hepatic injury, and rare cases of gallstone formation. Patients should report unexplained muscle pain, dark urine, or jaundice promptly.

Hyperlipen is contraindicated in patients with active liver disease, severe renal impairment, known hypersensitivity to ciprofibrate or other fibrates, and in individuals taking gemfibrozil. It should also be avoided in patients with a history of gallbladder disease unless specifically advised by a physician.